Cargando…
Tocilizumab for relapsing and remitting giant cell arteritis: a case series
BACKGROUND: Giant cell arteritis is a large vessel vasculitis of the arteries in the head and neck. The mainstay of management is with high-dose corticosteroids, and patients often face difficulties stopping or reducing steroids without recurrence of symptoms. Corticosteroids are well established to...
Autores principales: | Saha, Pratyasha, Srikantharajah, Denesh, Kaul, Arvind, Sofat, Nidhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607773/ https://www.ncbi.nlm.nih.gov/pubmed/36289554 http://dx.doi.org/10.1186/s13256-022-03625-y |
Ejemplares similares
-
Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case report
por: Butryn, Michaela, et al.
Publicado: (2021) -
Tongue necrosis secondary to giant cell arteritis, successfully treated with tocilizumab: a case report
por: Cho, Young Min, et al.
Publicado: (2023) -
Design of the Tocilizumab in Giant Cell Arteritis Trial
por: Unizony, Sebastian H., et al.
Publicado: (2013) -
Benchmarking tocilizumab use for giant cell arteritis
por: Conway, Richard, et al.
Publicado: (2022) -
Atypical Cogan's Syndrome Mimicking Giant Cell Arteritis Successfully Treated with Early Administration of Tocilizumab
por: Hara, Kazusato, et al.
Publicado: (2021)